Longboard Pharmaceuticals announces positive topline data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in participants with developmental and epileptic encephalopathies; webcast to be held today at 8:30 a.m. ET (6.03)
- Bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population
- A median seizure reduction of 72.1% in Dravet Syndrome (DS), 48.1% in Lennox-Gastaut Syndrome (LGS) and 61.2% in DEE Other was achieved
- Favorable safety and tolerability results
- Longboard is rapidly moving forward with preparations for its global Phase 3 program
- Longboard Pharmaceuticals +315% remains strong into the close
- Longboard Pharmaceuticals announces commencement of $150 mln public offering of common stock